{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=First+Line+Therapy&page=16", "query": { "condition": "First Line Therapy", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 1005, "total_pages": 101, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=First+Line+Therapy&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=First+Line+Therapy&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T01:00:17.708Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06008093", "title": "A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 103, "start_date": "2024-04-04", "completion_date": "2028-02-28", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-22T01:00:17.708Z", "location_count": 47, "location_summary": "Beverly Hills, California • La Jolla, California • Los Alamitos, California + 40 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06008093" }, { "nct_id": "NCT03420014", "title": "Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leiomyosarcoma" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "L19TNF plus doxorubicin", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Philogen S.p.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "16 Years to 100 Years" }, "enrollment_count": 114, "start_date": "2018-12-27", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2023-10-10", "last_synced_at": "2026-10-22T01:00:17.708Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Santa Monica, California • Jacksonville, Florida + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03420014" }, { "nct_id": "NCT02538666", "title": "An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 907, "start_date": "2015-10-13", "completion_date": "2021-11-11", "has_results": true, "last_update_posted_date": "2023-01-05", "last_synced_at": "2026-10-22T01:00:17.708Z", "location_count": 28, "location_summary": "Sacramento, California • New Haven, Connecticut • Fort Myers, Florida + 23 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02538666" }, { "nct_id": "NCT01694277", "title": "Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastrointestinal Stromal Tumors" ], "interventions": [ { "name": "Masitinib", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AB Science", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 258, "start_date": "2012-04", "completion_date": "2020-12", "has_results": false, "last_update_posted_date": "2020-12-08", "last_synced_at": "2026-10-22T01:00:17.708Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01694277" }, { "nct_id": "NCT00474786", "title": "Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Sorafenib", "type": "DRUG" }, { "name": "temsirolimus (Torisel)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 512, "start_date": "2007-09", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2013-11-21", "last_synced_at": "2026-10-22T01:00:17.708Z", "location_count": 26, "location_summary": "Duarte, California • La Jolla, California • Los Angeles, California + 19 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00474786" }, { "nct_id": "NCT03876769", "title": "Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-Cell Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "CTL019", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Year to 25 Years" }, "enrollment_count": 121, "start_date": "2019-06-24", "completion_date": "2027-10-19", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-22T01:00:17.708Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03876769" }, { "nct_id": "NCT01076751", "title": "Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostatic Neoplasms" ], "interventions": [], "intervention_types": [], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 82, "start_date": "2010-02", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2011-02-14", "last_synced_at": "2026-10-22T01:00:17.708Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01076751" }, { "nct_id": "NCT05253651", "title": "A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "tucatinib", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "levoleucovorin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2022-10-24", "completion_date": "2030-07-03", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-22T01:00:17.708Z", "location_count": 132, "location_summary": "Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 82 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05253651" }, { "nct_id": "NCT03298451", "title": "Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab (Regimen 1)", "type": "DRUG" }, { "name": "Tremelimumab (Regimen 2)", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Durvalumab (Regimen 1)", "type": "DRUG" }, { "name": "Durvalumab (Regimen 2)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 1324, "start_date": "2017-10-11", "completion_date": "2027-12-31", "has_results": true, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-22T01:00:17.708Z", "location_count": 20, "location_summary": "Los Angeles, California • Orange, California • San Francisco, California + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03298451" }, { "nct_id": "NCT01761266", "title": "A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma (HCC)" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 954, "start_date": "2013-03-01", "completion_date": "2021-03-10", "has_results": true, "last_update_posted_date": "2022-04-05", "last_synced_at": "2026-10-22T01:00:17.708Z", "location_count": 21, "location_summary": "Los Angeles, California • Sacramento, California • San Francisco, California + 18 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01761266" } ] }